Rossi, Giordano Novak; Hallak, Jaime Eduardo Cecilio 
; Saiz, José Carlos Bouso; Santos, Rafael Guimarães dos
Fonte: Expert Opinion on Drug Safety. Unidade: FMRP
Assuntos: ANTIDEPRESSIVOS, FÁRMACOS PSICOTRÓPICOS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROSSI, Giordano Novak et al. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, v. 21, n. 6, p. 761-776, 2022Tradução . . Disponível em: https://doi.org/10.1080/14740338.2022.2066650. Acesso em: 19 nov. 2025.APA
Rossi, G. N., Hallak, J. E. C., Saiz, J. C. B., & Santos, R. G. dos. (2022). Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opinion on Drug Safety, 21( 6), 761-776. doi:10.1080/14740338.2022.2066650NLM
Rossi GN, Hallak JEC, Saiz JCB, Santos RG dos. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges [Internet]. Expert Opinion on Drug Safety. 2022 ; 21( 6): 761-776.[citado 2025 nov. 19 ] Available from: https://doi.org/10.1080/14740338.2022.2066650Vancouver
Rossi GN, Hallak JEC, Saiz JCB, Santos RG dos. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges [Internet]. Expert Opinion on Drug Safety. 2022 ; 21( 6): 761-776.[citado 2025 nov. 19 ] Available from: https://doi.org/10.1080/14740338.2022.2066650
